Literature DB >> 32945966

Efficacy of radiofrequency ablation for recurrent thyroid cancer invading the airways.

Sae Rom Chung1, Jung Hwan Baek2, Young Jun Choi1, Tae-Yon Sung3, Dong Eun Song4, Tae Yong Kim5, Jeong Hyun Lee1.   

Abstract

OBJECTIVES: To evaluate the efficacy of radiofrequency ablation (RFA) in patients with recurrent thyroid cancer invading the airways.
METHODS: We reviewed patients who had undergone RFA for recurrent thyroid cancer in the central compartment after total thyroidectomy between January 2008 and December 2018. All tumors were classified according to their association with the laryngeal structure and trachea. The volume reduction rate (VRR) and complete disappearance rate were calculated, and their differences were determined relative to the association between the tumor and trachea. Complication rates associated with RFA were evaluated.
RESULTS: The study population included 119 patients with 172 recurrent tumors. Mean VRR was 81.2% ± 55.7%, with 124 tumors (72.1%) completely disappearing after a mean follow-up of 47.9 ± 35.4 months. The complete disappearance rate of recurrent tumors not in contact with the trachea was highest, followed by tumors forming acute angles, right angles, and obtuse angles with the trachea, and tumors with intraluminal tracheal invasion (p value < 0.001). The overall complication rate was 21.4%.
CONCLUSIONS: RFA is effective and safe for the local control of recurrent tumors in the central neck compartment after total thyroidectomy, even for tumors invading the airways, and may be considered an alternative to surgical resection. The inverse relationship between RFA efficacy and airway invasion suggests that early RFA may benefit patients with recurrent tumors in the central neck compartment. KEY POINTS: • RFA achieved a mean VRR of 81.2% ± 55.7% and complete disappearance of 124 tumors (72.1%) after a mean follow-up of 47.9 ± 35.4 months. • The complete disappearance rate of recurrent tumors not in contact with the trachea was the highest, followed by tumors forming acute angles, right angles, and obtuse angles with the trachea, and tumors with intraluminal tracheal invasion. • Stent-assisted RFA may be a good alternative for palliative treatment of recurrent tumors with intraluminal tracheal invasion.

Entities:  

Keywords:  Neoplasm recurrence, local; Radiofrequency ablation; Thyroid cancer, papillary; Treatment outcome; Ultrasonography

Mesh:

Year:  2020        PMID: 32945966     DOI: 10.1007/s00330-020-07283-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

Review 1.  Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis.

Authors:  Sae Rom Chung; Chong Hyun Suh; Jung Hwan Baek; Hye Sun Park; Young Jun Choi; Jeong Hyun Lee
Journal:  Int J Hyperthermia       Date:  2017-06-26       Impact factor: 3.914

2.  Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma.

Authors:  Liping Wang; Minghua Ge; Dong Xu; Liyu Chen; Chaowen Qian; Kaiyuan Shi; Junping Liu; Yong Chen
Journal:  J Cancer Res Ther       Date:  2014-11       Impact factor: 1.805

3.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

  3 in total
  7 in total

1.  European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions.

Authors:  Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini
Journal:  Eur Thyroid J       Date:  2021-05-25

2.  Assessment of thyroid-specific quality of life in patients with benign symptomatic thyroid nodules treated with radiofrequency or ethanol ablation: a prospective multicenter study.

Authors:  So Yeong Jeong; Eun Ju Ha; Jung Hwan Baek; Tae Yong Kim; Yu-Mi Lee; Jeong Hyun Lee; Jeonghun Lee
Journal:  Ultrasonography       Date:  2021-06-29

3.  Ultrasound-Guided Radiofrequency Ablation Versus Surgical Resection for the Treatment of T1bN0M0 Papillary Thyroid Carcinoma in Different Age Groups.

Authors:  Hongying He; Rilige Wu; Jiahang Zhao; Qing Song; Yan Zhang; Yukun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

4.  Radiofrequency Ablation of Papillary Thyroid Microcarcinomas.

Authors:  Leonardo Guimarães Rangel; Jose Higino Steck; Erivelto Martinho Volpi; Jonathon O Russell; Ralph P Tufano
Journal:  AACE Clin Case Rep       Date:  2022-02-16

5.  Radiofrequency ablation of recurrent thyroid cancers: anatomy-based management.

Authors:  Min Kyoung Lee; Jung Hwan Baek; Sae Rom Chung; Young Jun Choi; Jeong Hyun Lee; So Lyung Jung
Journal:  Ultrasonography       Date:  2021-12-21

6.  Efficacy of radiofrequency ablation for metastatic papillary thyroid cancer with and without initial biochemical complete status.

Authors:  Wen-Chieh Chen; Chen-Kai Chou; Yen-Hsiang Chang; Pi-Ling Chiang; Lay-San Lim; Shun-Yu Chi; Sheng-Dean Luo; Wei-Che Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-03       Impact factor: 6.055

Review 7.  Update of Radiofrequency Ablation for Treating Benign and Malignant Thyroid Nodules. The Future Is Now.

Authors:  Ralph P Tufano; Pia Pace-Asciak; Jonathon O Russell; Carlos Suárez; Gregory W Randolph; Fernando López; Ashok R Shaha; Antti Mäkitie; Juan P Rodrigo; Luiz Paulo Kowalski; Mark Zafereo; Peter Angelos; Alfio Ferlito
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.